… A finding of >12% resistance rates to both tigecycline and colistin, in our study, is of great
concern as the emergence of these strains may compromise the treatment of MDR Acineto…

… Patients receiving tigecycline for Acinetobacter should be monitored for the … We report a
case of the development of tigecycline resistance to MDR A. baumannii after brief tigecycline …

… However, clinical resistance has emerged recently and has been detected following … TIG
resistance is observed most frequently in Acinetobacter baumannii and Enterobacteriaceae, …

… baumannii is that FDA has not provided any proprietary tigecycline breakpoints for
Acinetobacter species (7). Date obtained from the current, and other studies indicated increased …

… Tigecycline has also shown adequate activity against Acinetobacter species of potential …
clinical reports of cases of development of resistance during tigecycline therapy for MDR A. …

… Acinetobacter species and explored the evolutionary history of Tet(X)-like monooxygenases.
Further studies are needed to evaluate the clinical impact of these mobile tigecycline …

… emergence of resistance to colistin or tigecycline during treatment, in most cases (86%)
resulting in persistent or recurrent infections, especially in cases of emergent … of tigecycline were …

… A prospective study was conducted to report emergence of PDR Acb complex which were
also resistant to tigecycline and colistin. All consecutive isolates of Acb complex obtained …

… had a history of tigecycline therapy, while the remaining TNAB patients had never been treated
with tigecycline. … the emergence and wide dissemination of tigecycline-nonsusceptible A. …

… compared to that in a tigecycline-susceptible isolate. In vitro exposure of a tigecycline-susceptible
clinical strain to tigecycline caused a rapid rise in the MIC of tigecycline from 2 μg/ml to …